Add BrightSurf on Google Email

Titanium particles are common around implants

A new study from the University of Gothenburg found that titanium micro-particles are consistently present at all examined implants, even those without signs of inflammation. The researchers identified 14 genes that may be affected by these particles, but further research is needed to understand their impact on tissue health.

SourceUniversity of Gothenburg·JournalCommunications Medicine·TypeObservational study·DateApr 9, 2025

Burning cancer's bridges

Researchers discovered that aggressive breast cancer prompts nearby immune cells to build 'molecular bridges' between themselves, suppressing the immune response. An antibody treatment that blocks these bridges was shown to restore the immune system's ability to attack with force, inhibiting tumor growth in a mouse model.

SourceWeizmann Institute of Science·JournalCell Reports·DateDec 23, 2024

Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified the protein TYRP1 as a promising target for CAR T-cell therapy. The study demonstrates potent antitumor responses against cutaneous and rare melanoma types, offering new hope for treating these challenging-to-treat cancers.

Cancer's sweet Achilles heel

A team of researchers at Kyoto University has found that a deficiency in the enzyme B4GALT3 inhibits tumor growth in mice. The study shows that reduced glycosylation on T cell surfaces correlates with increased CD8+ immune cells infiltrating tumors.

SourceKyoto University·JournalFrontiers in Immunology·TypeExperimental study·DateOct 25, 2023

JCI Table of Contents, April 1, 2003

Inhibition of RAGE suppressed neointimal formation in mice upon arterial injury and decreased SMC proliferation, migration, and expression of ECM proteins. Local mucosal immunization leads to antigen-specific IgA production at distant mucosal sites through the interaction between CCR10 and its mucosal epithelial ligand MEC.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateApr 1, 2003

Intrakine blockade of a chemokine receptor

Researchers developed an Intrakine blockade to block a specific chemokine receptor, leading to reduced inflammation and modulated immune responses in various disease models. This breakthrough could provide new therapeutic avenues for treating conditions like asthma, autoimmune diseases, and cancer.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJul 11, 2001